MIT Technology Review published a feature on February 23 documenting what anyone in the peptide space already knew — and what the rest of the world is just discovering: peptides have crossed from niche biohacking subculture into mainstream wellness culture.

The reporting captures a specific cultural moment. At a health-technology startup in Los Angeles, employees receive free peptide shots on Fridays. A health food store in Phoenix displays a sidewalk sign reading “We have peptides!” People are injecting, snorting, and combining compounds into protocols with names like “the Wolverine stack.” The ground that used to be occupied by a few thousand informed self-experimenters on Reddit is now a consumer market.

The article identifies the structural problems with this expansion. The most popular injectable peptides — BPC-157, TB-500, CJC-1295, ipamorelin — have never completed the clinical trial process that would establish human safety and efficacy. They are sold as “research chemicals” through an online marketplace that exists in a regulatory gray zone. The vast majority of supply originates in Chinese synthesis facilities that operate outside any pharmaceutical regulatory framework.

The political context matters: HHS Secretary Kennedy has framed the peptide question as consumer access versus regulatory overreach. The MIT Technology Review piece does not endorse that framing — it presents a landscape in which consumer demand has outrun both the evidence base and the regulatory infrastructure.

For Peptidings readers, the mainstream arrival of peptides is a double-edged development. Greater visibility may accelerate clinical research funding and legitimate pharmaceutical development. It will also amplify misinformation, attract bad actors to the supply chain, and create pressure to overstate evidence in pursuit of an audience that is now orders of magnitude larger than it was 18 months ago.